The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer
The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va expression has not been examined in transbronchial biopsy specimens. We retrospectively examined the relationship between ACTN4va e...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2015-03, Vol.35 (3), p.1663-1667 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1667 |
|---|---|
| container_issue | 3 |
| container_start_page | 1663 |
| container_title | Anticancer research |
| container_volume | 35 |
| creator | Okamoto, Norio Suzuki, Hidekazu Kawahara, Kunimitsu Honda, Kazufumi Miura, Nami Hirashima, Tomonori Tamiya, Motohiro Morishita, Naoko Shiroyama, Takayuki Tanaka, Ayako Tani, Eriko Hamaguchi, Masanari Kitani, Masashi Yamada, Tesshi Kawase, Ichiro |
| description | The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va expression has not been examined in transbronchial biopsy specimens.
We retrospectively examined the relationship between ACTN4va expression, clinical factors and survival in 104 consecutive newly-diagnosed SCLC patients.
Of the 104 screened cases, 83 (median age=69 years; transbronchial biopsy, 71) were included in our study. Survival was significantly different in the group with no distant metastasis (1996 vs. 422 days, respectively; p=0.000115) but was not significantly different with regard to ACTN4va expression in the group with distant metastasis (293 vs. 254 days, respectively; p=0.678).
ACTN4va expression was identifiable in small biopsy samples. ACTN4va expression was also significantly related to distant metastasis and could stratify SCLC patients according to prognosis. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661988391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661988391</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-ad5a3f0cd08b991155bd8d3c65e9c2cafb3dee153faa6d1e4729e4d11f709b773</originalsourceid><addsrcrecordid>eNo1kMtqwzAUREWhNGnaXyhadmOQrMiyliX0BYFu0rW5lq5TNbLsSnIgf1-XJjAwm2E4M1dkyZXmhZKCLchtSt-MVZWuxQ1ZlFJJJkq5JIfdF1LwGWOA7I7oTzSN3hm0FEx2wYViTY8QHYRMIVGgYxz2YUjZGdpDPGCk3RBpjxnSLJeoCzT14H1h0Hvqp7CnBoLBeEeuO_AJ78--Ip8vz7vNW7H9eH3fPG2LseQ8F2AliI4Zy-pWa86lbG1thakkalMa6FphEbkUHUBlOa5VqXFtOe8U061SYkUe_3tn1J8JU256l_5gIOAwpYZXFdd1LTSfow_n6NT2aJsxunnUqbkcJH4BgTZi6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661988391</pqid></control><display><type>article</type><title>The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Okamoto, Norio ; Suzuki, Hidekazu ; Kawahara, Kunimitsu ; Honda, Kazufumi ; Miura, Nami ; Hirashima, Tomonori ; Tamiya, Motohiro ; Morishita, Naoko ; Shiroyama, Takayuki ; Tanaka, Ayako ; Tani, Eriko ; Hamaguchi, Masanari ; Kitani, Masashi ; Yamada, Tesshi ; Kawase, Ichiro</creator><creatorcontrib>Okamoto, Norio ; Suzuki, Hidekazu ; Kawahara, Kunimitsu ; Honda, Kazufumi ; Miura, Nami ; Hirashima, Tomonori ; Tamiya, Motohiro ; Morishita, Naoko ; Shiroyama, Takayuki ; Tanaka, Ayako ; Tani, Eriko ; Hamaguchi, Masanari ; Kitani, Masashi ; Yamada, Tesshi ; Kawase, Ichiro</creatorcontrib><description>The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va expression has not been examined in transbronchial biopsy specimens.
We retrospectively examined the relationship between ACTN4va expression, clinical factors and survival in 104 consecutive newly-diagnosed SCLC patients.
Of the 104 screened cases, 83 (median age=69 years; transbronchial biopsy, 71) were included in our study. Survival was significantly different in the group with no distant metastasis (1996 vs. 422 days, respectively; p=0.000115) but was not significantly different with regard to ACTN4va expression in the group with distant metastasis (293 vs. 254 days, respectively; p=0.678).
ACTN4va expression was identifiable in small biopsy samples. ACTN4va expression was also significantly related to distant metastasis and could stratify SCLC patients according to prognosis.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 25750325</identifier><language>eng</language><publisher>Greece</publisher><subject>Actinin - analysis ; Actinin - genetics ; Aged ; Aged, 80 and over ; Alternative Splicing ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; Biopsy ; Female ; Humans ; Lung Neoplasms - chemistry ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies ; Small Cell Lung Carcinoma - chemistry ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - pathology</subject><ispartof>Anticancer research, 2015-03, Vol.35 (3), p.1663-1667</ispartof><rights>Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25750325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okamoto, Norio</creatorcontrib><creatorcontrib>Suzuki, Hidekazu</creatorcontrib><creatorcontrib>Kawahara, Kunimitsu</creatorcontrib><creatorcontrib>Honda, Kazufumi</creatorcontrib><creatorcontrib>Miura, Nami</creatorcontrib><creatorcontrib>Hirashima, Tomonori</creatorcontrib><creatorcontrib>Tamiya, Motohiro</creatorcontrib><creatorcontrib>Morishita, Naoko</creatorcontrib><creatorcontrib>Shiroyama, Takayuki</creatorcontrib><creatorcontrib>Tanaka, Ayako</creatorcontrib><creatorcontrib>Tani, Eriko</creatorcontrib><creatorcontrib>Hamaguchi, Masanari</creatorcontrib><creatorcontrib>Kitani, Masashi</creatorcontrib><creatorcontrib>Yamada, Tesshi</creatorcontrib><creatorcontrib>Kawase, Ichiro</creatorcontrib><title>The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va expression has not been examined in transbronchial biopsy specimens.
We retrospectively examined the relationship between ACTN4va expression, clinical factors and survival in 104 consecutive newly-diagnosed SCLC patients.
Of the 104 screened cases, 83 (median age=69 years; transbronchial biopsy, 71) were included in our study. Survival was significantly different in the group with no distant metastasis (1996 vs. 422 days, respectively; p=0.000115) but was not significantly different with regard to ACTN4va expression in the group with distant metastasis (293 vs. 254 days, respectively; p=0.678).
ACTN4va expression was identifiable in small biopsy samples. ACTN4va expression was also significantly related to distant metastasis and could stratify SCLC patients according to prognosis.</description><subject>Actinin - analysis</subject><subject>Actinin - genetics</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alternative Splicing</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biopsy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - chemistry</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Small Cell Lung Carcinoma - chemistry</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - pathology</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtqwzAUREWhNGnaXyhadmOQrMiyliX0BYFu0rW5lq5TNbLsSnIgf1-XJjAwm2E4M1dkyZXmhZKCLchtSt-MVZWuxQ1ZlFJJJkq5JIfdF1LwGWOA7I7oTzSN3hm0FEx2wYViTY8QHYRMIVGgYxz2YUjZGdpDPGCk3RBpjxnSLJeoCzT14H1h0Hvqp7CnBoLBeEeuO_AJ78--Ip8vz7vNW7H9eH3fPG2LseQ8F2AliI4Zy-pWa86lbG1thakkalMa6FphEbkUHUBlOa5VqXFtOe8U061SYkUe_3tn1J8JU256l_5gIOAwpYZXFdd1LTSfow_n6NT2aJsxunnUqbkcJH4BgTZi6w</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Okamoto, Norio</creator><creator>Suzuki, Hidekazu</creator><creator>Kawahara, Kunimitsu</creator><creator>Honda, Kazufumi</creator><creator>Miura, Nami</creator><creator>Hirashima, Tomonori</creator><creator>Tamiya, Motohiro</creator><creator>Morishita, Naoko</creator><creator>Shiroyama, Takayuki</creator><creator>Tanaka, Ayako</creator><creator>Tani, Eriko</creator><creator>Hamaguchi, Masanari</creator><creator>Kitani, Masashi</creator><creator>Yamada, Tesshi</creator><creator>Kawase, Ichiro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201503</creationdate><title>The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer</title><author>Okamoto, Norio ; Suzuki, Hidekazu ; Kawahara, Kunimitsu ; Honda, Kazufumi ; Miura, Nami ; Hirashima, Tomonori ; Tamiya, Motohiro ; Morishita, Naoko ; Shiroyama, Takayuki ; Tanaka, Ayako ; Tani, Eriko ; Hamaguchi, Masanari ; Kitani, Masashi ; Yamada, Tesshi ; Kawase, Ichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-ad5a3f0cd08b991155bd8d3c65e9c2cafb3dee153faa6d1e4729e4d11f709b773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Actinin - analysis</topic><topic>Actinin - genetics</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alternative Splicing</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biopsy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - chemistry</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Small Cell Lung Carcinoma - chemistry</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okamoto, Norio</creatorcontrib><creatorcontrib>Suzuki, Hidekazu</creatorcontrib><creatorcontrib>Kawahara, Kunimitsu</creatorcontrib><creatorcontrib>Honda, Kazufumi</creatorcontrib><creatorcontrib>Miura, Nami</creatorcontrib><creatorcontrib>Hirashima, Tomonori</creatorcontrib><creatorcontrib>Tamiya, Motohiro</creatorcontrib><creatorcontrib>Morishita, Naoko</creatorcontrib><creatorcontrib>Shiroyama, Takayuki</creatorcontrib><creatorcontrib>Tanaka, Ayako</creatorcontrib><creatorcontrib>Tani, Eriko</creatorcontrib><creatorcontrib>Hamaguchi, Masanari</creatorcontrib><creatorcontrib>Kitani, Masashi</creatorcontrib><creatorcontrib>Yamada, Tesshi</creatorcontrib><creatorcontrib>Kawase, Ichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okamoto, Norio</au><au>Suzuki, Hidekazu</au><au>Kawahara, Kunimitsu</au><au>Honda, Kazufumi</au><au>Miura, Nami</au><au>Hirashima, Tomonori</au><au>Tamiya, Motohiro</au><au>Morishita, Naoko</au><au>Shiroyama, Takayuki</au><au>Tanaka, Ayako</au><au>Tani, Eriko</au><au>Hamaguchi, Masanari</au><au>Kitani, Masashi</au><au>Yamada, Tesshi</au><au>Kawase, Ichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2015-03</date><risdate>2015</risdate><volume>35</volume><issue>3</issue><spage>1663</spage><epage>1667</epage><pages>1663-1667</pages><eissn>1791-7530</eissn><abstract>The alternatively spliced actinin-4 variant (ACTN4va) is expressed in small-cell lung cancer (SCLC) and is thought to be a potential diagnostic marker. However, ACTN4va expression has not been examined in transbronchial biopsy specimens.
We retrospectively examined the relationship between ACTN4va expression, clinical factors and survival in 104 consecutive newly-diagnosed SCLC patients.
Of the 104 screened cases, 83 (median age=69 years; transbronchial biopsy, 71) were included in our study. Survival was significantly different in the group with no distant metastasis (1996 vs. 422 days, respectively; p=0.000115) but was not significantly different with regard to ACTN4va expression in the group with distant metastasis (293 vs. 254 days, respectively; p=0.678).
ACTN4va expression was identifiable in small biopsy samples. ACTN4va expression was also significantly related to distant metastasis and could stratify SCLC patients according to prognosis.</abstract><cop>Greece</cop><pmid>25750325</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2015-03, Vol.35 (3), p.1663-1667 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1661988391 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Actinin - analysis Actinin - genetics Aged Aged, 80 and over Alternative Splicing Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Biopsy Female Humans Lung Neoplasms - chemistry Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Neoplasm Metastasis Prognosis Retrospective Studies Small Cell Lung Carcinoma - chemistry Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - pathology |
| title | The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T03%3A03%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20alternatively%20spliced%20actinin-4%20variant%20as%20a%20prognostic%20marker%20for%20metastasis%20in%20small-cell%20lung%20cancer&rft.jtitle=Anticancer%20research&rft.au=Okamoto,%20Norio&rft.date=2015-03&rft.volume=35&rft.issue=3&rft.spage=1663&rft.epage=1667&rft.pages=1663-1667&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1661988391%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661988391&rft_id=info:pmid/25750325&rfr_iscdi=true |